Ex­pe­dit­ed CMC readi­ness pi­lot in­creas­es com­mu­ni­ca­tions be­tween FDA and spon­sors

As drug short­ages — for cru­cial drugs for can­cer, AD­HD, and di­a­betes — con­tin­ue na­tion­wide, the FDA is pin­point­ing man­u­fac­tur­ing as an area of crit­i­cal need. To­day, the agency un­veiled more de­tails on a new CMC pi­lot, once float­ed to launch last April. It seeks to help com­pa­nies im­prove their chem­istry, man­u­fac­tur­ing and con­trols readi­ness via ad­di­tion­al in­ter­ac­tions with the agency.

The pi­lot, which will start ac­cept­ing ap­pli­ca­tions on Oct. 3 as an amend­ment to an ac­tive IND, is part of the com­mit­ments that the FDA made un­der PDU­FA VII, which is the user fee agree­ment be­tween in­dus­try and FDA that sub­si­dizes the agency’s re­views, and the pi­lot will run through the end of FY 2027.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER